Company
MicroCures' founder and Chief Scientific Officer, David Sharp, Ph.D., is one of the world's foremost experts on cell movement.
Dr. Sharp’s pioneering research has helped highlight the critical role that cell movement plays in all repair and regeneration within the human body. Based on this groundbreaking science, the company has established a first-of-its-kind therapeutic platform capable of precisely controlling the speed and direction of cell movement in oder to address a wide range of indications.
This novel scientific approach offers the potential to deliver powerful therapeutic benefits for a variety of large and underserved medical applications. Microcures has created a broad pipeline of therapeutic programs with an initial focus in the area of tissue, nerve and organ repair. Unlike other regenerative medicine approaches that rely upon engineered materials or systemic growth factor/stem cell therapeutics, MicroCures’ technology directs and enhances the body’s inherent tissue repair processes through local, non-systemic, and temporary modulation of cell motility.
MicroCures is rapidly advancing its three parallel programs for clinical trials. Multiple preclinical studies have demonstrated that the company’s technology produces statistically significant improvement and acceleration of tissue repair in three therapeutic pathways with large unmet need markets: corneal, peripheral nerve, and dermal.
The company’s pipeline also includes follow-on cell motility acceleration programs focused on burn healing, central nerve regeneration and cardiac repair, as well as earlier-stage cell motility deceleration work designed to combat cancer metastases and fibrosis.
Proprietary technology to accelerate wound repair
MicroCures has developed a proprietary siRNA-based drug candidate designed to silence the activity of the enzyme fidgetin-like 2 (FL2), thereby both accelerating the rate and improving the quality of wound repair.
Play Video
Positioned as an industry leader
The company has built an extensive intellectual property estate offering protection for its underlying technology, as well as the therapeutic programs that have emerged from the platform. This comprehensive patent portfolio positions the company as the industry leader in therapeutic modulation of cell movement, while providing numerous partnering and licensing opportunities.